SQZ Bio Stock (NYSE:SQZ)


ForecastOwnershipChart

Previous Close

$0.27

52W Range

$0.25 - $3.56

50D Avg

$0.55

200D Avg

$1.24

Market Cap

$12.83M

Avg Vol (3M)

$553.61K

Beta

2.71

Div Yield

-

SQZ Company Profile


SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

53

IPO Date

Oct 30, 2020

Website

SQZ Performance


Peer Comparison


TickerCompany
SNTISenti Biosciences, Inc.
NUVBNuvation Bio Inc.
PMVPPMV Pharmaceuticals, Inc.
FRTXFresh Tracks Therapeutics, Inc.
MNPRMonopar Therapeutics Inc.
IKTInhibikase Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
FENCFennec Pharmaceuticals Inc.
HILSTharimmune, Inc.
ANTXAN2 Therapeutics, Inc.
HOWLWerewolf Therapeutics, Inc.
CADLCandel Therapeutics, Inc.
PCSAProcessa Pharmaceuticals, Inc.
THRDThird Harmonic Bio, Inc.
ANEBAnebulo Pharmaceuticals, Inc.
LIPOLipella Pharmaceuticals Inc.
NLTXNeurogene Inc.
KZRKezar Life Sciences, Inc.